Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sailaja Puttagunta

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Frontiers in Bioscience : a Journal and Virtual Library|April 18, 2003
Cardiac manifestations of HIVMajid Sadigh, Sailaja Puttagunta
Annals of Clinical Microbiology and Antimicrobials|April 18, 2015
Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studiesMichael W Dunne, Dan Sahm, Sailaja Puttagunta
Journal of Clinical Microbiology|June 26, 2023
Sulopenem Disk Development, Quality Control Range, and MIC to Disk Result Correlation for <i>Enterobacterales</i> IsolatesSailaja Puttagunta, Steven I Aronin, Jeanna DiFranco-Fisher, et al.
BMC Infectious Diseases|November 28, 2013
A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international studyAndrew A Quartin, Ernesto G Scerpella, Sailaja Puttagunta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2015
A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure InfectionMichael W Dunne, Sailaja Puttagunta, Philip Giordano, et al.
Microbiology Spectrum|February 9, 2022
Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible <i>Enterobacterales</i>Michael W Dunne, Sailaja Puttagunta, Steven I Aronin, et al.
Clinical Drug Investigation|October 14, 2015
Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese SubjectsPatrick J Scoble, Robert C Owens, Sailaja Puttagunta, et al.
Drug Safety|December 31, 2015
Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative StudiesMichael W Dunne, George H Talbot, Helen W Boucher, et al.
Antimicrobial Agents and Chemotherapy|January 7, 2015
Extended-duration dosing and distribution of dalbavancin into bone and articular tissueMichael W Dunne, Sailaja Puttagunta, Craig R Sprenger, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2015
In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance ProgramSandra P McCurdy, Ronald N Jones, Rodrigo E Mendes, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Frontiers in Bioscience : a Journal and Virtual Library|April 18, 2003
Cardiac manifestations of HIVMajid Sadigh, Sailaja Puttagunta
Annals of Clinical Microbiology and Antimicrobials|April 18, 2015
Use of vancomycin as a surrogate for dalbavancin in vitro susceptibility testing: results from the DISCOVER studiesMichael W Dunne, Dan Sahm, Sailaja Puttagunta
Journal of Clinical Microbiology|June 26, 2023
Sulopenem Disk Development, Quality Control Range, and MIC to Disk Result Correlation for <i>Enterobacterales</i> IsolatesSailaja Puttagunta, Steven I Aronin, Jeanna DiFranco-Fisher, et al.
BMC Infectious Diseases|November 28, 2013
A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international studyAndrew A Quartin, Ernesto G Scerpella, Sailaja Puttagunta, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 28, 2015
A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure InfectionMichael W Dunne, Sailaja Puttagunta, Philip Giordano, et al.
Microbiology Spectrum|February 9, 2022
Impact of Empirical Antibiotic Therapy on Outcomes of Outpatient Urinary Tract Infection Due to Nonsusceptible <i>Enterobacterales</i>Michael W Dunne, Sailaja Puttagunta, Steven I Aronin, et al.
Clinical Drug Investigation|October 14, 2015
Pharmacokinetics, Safety, and Tolerability of a Single 500-mg or 1000-mg Intravenous Dose of Dalbavancin in Healthy Japanese SubjectsPatrick J Scoble, Robert C Owens, Sailaja Puttagunta, et al.
Drug Safety|December 31, 2015
Safety of Dalbavancin in the Treatment of Skin and Skin Structure Infections: A Pooled Analysis of Randomized, Comparative StudiesMichael W Dunne, George H Talbot, Helen W Boucher, et al.
Antimicrobial Agents and Chemotherapy|January 7, 2015
Extended-duration dosing and distribution of dalbavancin into bone and articular tissueMichael W Dunne, Sailaja Puttagunta, Craig R Sprenger, et al.
Antimicrobial Agents and Chemotherapy|May 20, 2015
In Vitro Activity of Dalbavancin against Drug-Resistant Staphylococcus aureus Isolates from a Global Surveillance ProgramSandra P McCurdy, Ronald N Jones, Rodrigo E Mendes, et al.
Pageof 4